Chemically induced pluripotent stem cell therapy - DNAmicroarray

Drug Profile

Chemically induced pluripotent stem cell therapy - DNAmicroarray

Alternative Names: CiPSC; CiPSC - Blood cells; CiPSC - Cardiovascular; CiPSC - Neuronal

Latest Information Update: 01 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DNAmicroarray
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Blood dyscrasias; Cardiovascular disorders; Neurological disorders

Highest Development Phases

  • Preclinical Blood dyscrasias; Cardiovascular disorders; Neurological disorders

Most Recent Events

  • 01 Aug 2016 Chemically induced pluripotent stem cell therapy - DNAmicroarray is available for licensing as of 01 Aug 2016. http://www.dnamicroarray.com/
  • 01 Aug 2016 Preclinical trials in Blood dyscrasias in USA (Parenteral)
  • 01 Aug 2016 Preclinical trials in Cardiovascular disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top